CN110694038A - External traditional Chinese medicine composition for treating cholecystitis - Google Patents
External traditional Chinese medicine composition for treating cholecystitis Download PDFInfo
- Publication number
- CN110694038A CN110694038A CN201910981506.8A CN201910981506A CN110694038A CN 110694038 A CN110694038 A CN 110694038A CN 201910981506 A CN201910981506 A CN 201910981506A CN 110694038 A CN110694038 A CN 110694038A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- cholecystitis
- fresh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 201000001352 cholecystitis Diseases 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 14
- 235000008397 ginger Nutrition 0.000 claims abstract description 14
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 12
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 12
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 12
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims abstract description 12
- 235000002594 Solanum nigrum Nutrition 0.000 claims abstract description 12
- 241000501743 Gentiana macrophylla Species 0.000 claims abstract description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 11
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 11
- 240000008042 Zea mays Species 0.000 claims abstract description 11
- 240000003146 Lobelia chinensis Species 0.000 claims abstract description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 10
- 240000002307 Solanum ptychanthum Species 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 241000729173 Cirsium japonicum Species 0.000 claims abstract description 9
- 241000239226 Scorpiones Species 0.000 claims abstract description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 9
- 235000005822 corn Nutrition 0.000 claims abstract description 9
- 244000116484 Inula helenium Species 0.000 claims abstract description 5
- 235000002598 Inula helenium Nutrition 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 3
- 241000219099 Parthenocissus quinquefolia Species 0.000 claims abstract 2
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract 2
- 239000002994 raw material Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 31
- 208000002193 Pain Diseases 0.000 abstract description 26
- 210000004185 liver Anatomy 0.000 abstract description 22
- 238000000034 method Methods 0.000 abstract description 18
- 230000001737 promoting effect Effects 0.000 abstract description 15
- 208000004880 Polyuria Diseases 0.000 abstract description 11
- 230000035619 diuresis Effects 0.000 abstract description 11
- 210000001835 viscera Anatomy 0.000 abstract description 6
- 230000004087 circulation Effects 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 239000011148 porous material Substances 0.000 abstract description 4
- 239000012466 permeate Substances 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 230000010415 tropism Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 241000234314 Zingiber Species 0.000 description 11
- 238000010926 purge Methods 0.000 description 11
- 241000563984 Ampelopsis Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 241000219061 Rheum Species 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 235000008216 herbs Nutrition 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 206010008617 Cholecystitis chronic Diseases 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000000197 Acute Cholecystitis Diseases 0.000 description 5
- 206010008614 Cholecystitis acute Diseases 0.000 description 5
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 208000001130 gallstones Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000522620 Scorpio Species 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 201000001883 cholelithiasis Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000009490 scorpio Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 2
- 241000219050 Polygonaceae Species 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 244000061457 Solanum nigrum Species 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 230000002279 cholagogic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000020694 gallbladder disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000020888 liquid diet Nutrition 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- 241000123835 Ampelopsis japonica Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010061695 Biliary tract infection Diseases 0.000 description 1
- 241000239225 Buthidae Species 0.000 description 1
- 206010006987 Calculus bladder Diseases 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000004845 Cholecystolithiasis Diseases 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010062693 Gallbladder enlargement Diseases 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000039951 Lithocarpus glaber Species 0.000 description 1
- 241001481692 Mesobuthus martensii Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000000210 bladder calculus Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an external traditional Chinese medicine composition for treating cholecystitis, which consists of scorpion (living or fresh), ginger (fresh), corn stigma (fresh), elecampane, indigo naturalis, Japanese thistle herb, rhubarb, gentiana macrophylla, Chinese lobelia, Japanese ampelopsis root, angelica dahurica, safflower, salvia miltiorrhiza, black nightshade and liquorice, by taking the integral treatment theory of traditional Chinese medicine as guidance, the ' surgical method, the most important external treatment, the ' skin separation and hair and orifices communication, the viscera do not directly reach the viscera ', the external medicine of the external treatment method of the traditional Chinese medicine is used for aiming at the etiology and pathogenesis of the cholecystitis, the traditional Chinese medicine composition is applied to the gallbladder region by taking general as a method and taking pain as an acupoint for promoting the circulation of qi, so that the medicine permeates from pores to adjust the interior of the body, thereby achieving the effects of clearing internal heat, clearing heat, promoting diuresis, soothing liver and gallbladder and treating cholecystitis, and has good clinical use value and popularization value.
Description
Technical Field
The invention relates to an external traditional Chinese medicine composition for treating cholecystitis.
Background
Cholecystitis is a common digestive tract disease, the incidence rate of female cholecystitis is higher than that of male cholecystitis, and the incidence rate of cholecystitis in China has a continuously increasing trend along with the change of the dietary structure of residents in recent years. Western medicine classifies cholecystitis into acute cholecystitis and chronic cholecystitis according to its clinical manifestations. The causes of cholecystitis are considered to include: twisting the bile duct; biliary obstruction and incarceration caused by gall bladder or bile duct calculi and biliary ascariasis or biliary tumor; physiological cystic wall of the old is fat and thick, and the contraction function of the biliary tract is reduced, which causes bile stasis and the like. The pathogenesis of cholecystitis is probably related to the reduction of blood perfusion of gallbladder and surrounding tissues, the increase and stimulation of bile salt concentration, the reflux of pancreatic juice in the biliary tract and the like, and the cholecystitis is caused by ischemic injury, hyperemia and edema, bacterial infection, necrosis and the like of the gallbladder. The modern western medicine treatment method for cholecystitis comprises antibacterial and anti-inflammatory, spasmolytic and analgesic, gastrointestinal decompression, fasting or liquid diet, low-fat meal for reducing bile secretion, oral cholagogic drugs such as magnesium sulfate solution, surgical cholecystectomy treatment and the like.
According to the clinical manifestations of cholecystitis diseases, the traditional Chinese medicine belongs to the categories of hypochondriac pain, gallbladder distention, jaundice and the like, the traditional Chinese medicine cholecystitis treatment documents are recorded more, the ancient famous medical works of China, the book Nei Jing, have been involved in hunting, for example, the book Ling Shu & Wu Chong says that the pathogen is in the liver and then the pain in the two hypochondriac regions, the book Ling Shu & Xue Lun says that the gallbladder is distended, the pain in the hypochondriac region is distended, the mouth is bitter and the good way, the book Ling Shu & Ben Zai says that the gallbladder is distended, the hypochondriac region is full and the pain is led to the lower abdomen, for example, the book Su Wen Miao Lun says that the pathogen is in the collateral of shaoyang and causes the. Gallbladder is one of six fu-organs in the theory of traditional Chinese medicine, so-called the "middle-positive organ" to make a decision, the disease of cholecystitis is localized in gallbladder and the liver and gallbladder are both exterior and interior, and the disease of cholecystitis is caused by improper diet, improper work and rest, emotional disorder, invasion of insect poison and the like, and stagnation of qi by liver depression and invasion of stomach by liver qi lead to the disease of qi stagnation, fu-organ qi obstruction, incoordination between spleen and stomach and damp-heat retention.
The invention relates to an externally applied traditional Chinese medicine composition for treating cholecystitis, which is an externally applied medicine for external treatment by using traditional Chinese medicine as guidance, and the method of external treatment by using traditional Chinese medicine is the most important method of external treatment by surgical operation. Ri \28729ZhouFang said that all the diseases are treated externally, so the doctor has the external treatment method. The internal treatment principle is the external treatment principle, and the external treatment principle is the internal treatment principle, without the special internal treatment of teaching people. "the skin separates and the hair opens, and the zang-fu organs do not reach the zang-fu organs, so the medicine permeates through the pores to regulate the interior of the body. Aiming at the pathogenesis of cholecystitis, the traditional Chinese medicine composition is used for dredging, and the method of dredging is used for promoting the movement of vital energy and guiding, so that the effects of soothing liver and benefiting gallbladder, clearing internal heat and purging intense heat, clearing heat and detoxicating, excreting and transforming damp evil, dissolving stasis and relieving pain are achieved, and the cholecystitis is treated.
Disclosure of Invention
The invention aims to provide an external traditional Chinese medicine composition for treating cholecystitis.
In order to realize the purpose of the invention of the external traditional Chinese medicine composition for treating cholecystitis, the invention prepares the raw material medicaments of the effective components of the external traditional Chinese medicine composition and the weight ratio of the raw material medicaments are as follows: 1-3 parts of scorpion (living, fresh), 6-8 parts of ginger (fresh), 18-22 parts of corn stigma (fresh), 5-7 parts of elecampane, 0.5-1.5 parts of indigo naturalis, 7-9 parts of Japanese thistle herb, 6-8 parts of rhubarb, 5-7 parts of gentiana macrophylla, 6-8 parts of Chinese lobelia, 5-7 parts of Japanese ampelopsis, 5-7 parts of angelica dahurica, 3-5 parts of safflower, 5-7 parts of salvia miltiorrhiza, 9-11 parts of black nightshade and 5-7 parts of liquorice.
The external traditional Chinese medicine composition for treating cholecystitis is prepared from the following raw materials in a preferable formula: 2 parts of scorpion (living for fresh use), 7 parts of ginger (fresh for fresh use), 20 parts of corn stigma (fresh for fresh use), 6 parts of elecampane, 1 part of indigo naturalis, 8 parts of Japanese thistle herb, 7 parts of rhubarb, 6 parts of gentiana macrophylla, 7 parts of Chinese lobelia, 6 parts of Japanese ampelopsis root, 6 parts of angelica dahurica, 4 parts of safflower, 6 parts of salvia miltiorrhiza, 10 parts of black nightshade and 6 parts of liquorice.
The invention relates to an external traditional Chinese medicine composition for treating cholecystitis, which consists of scorpion (living, fresh), ginger (fresh), corn stigma (fresh), elecampane, indigo naturalis, Japanese thistle herb, rhubarb, gentiana macrophylla, Chinese lobelia, Japanese ampelopsis root, angelica dahurica, safflower, salvia miltiorrhiza, black nightshade and liquorice. Wherein:
the Scorpio is whole body of Buthus martensii Karsch of Buthidae. Pungent, mild and toxic in nature and flavor. Meridian tropism enters liver meridian. The main functions are counteracting toxic pathogen and dissipating stagnation, dredging collaterals, removing blood stasis and relieving pain.
The rhizoma Zingiberis recens is fresh rhizome of Zingiber officinale Roscoe of Zingiberaceae. Pungent in nature and slightly warm in flavor. Meridian tropism enters lung, spleen and stomach meridians. The functions are mainly used for promoting blood circulation and removing blood stasis, promoting blood circulation and removing obstruction in channels, warming middle energizer and arresting vomiting, and promoting qi circulation and dispelling cold.
Stigma Maydis is the flower column and flower head of Zea mays of Zea of Gramineae. Sweet, bland and mild in nature and taste. Meridian tropism is classified into bladder, liver and gallbladder meridians. The functions are mainly used for clearing damp-heat, eliminating jaundice, inducing diuresis to alleviate edema, relaxing the bowels to descend qi, calming the liver and benefiting the gallbladder.
Radix aucklandiae is dried root of radix aucklandiae of Compositae. Pungent, bitter and warm in nature. The meridian entered in spleen, stomach, large intestine, triple energizer and gallbladder. The functions are mainly used for promoting qi circulation and relieving pain, strengthening spleen, warming middle-jiao and stomach, mainly treating pathogenic qi, preventing toxic plague, treating toxic swelling and dispelling cold stagnation.
Indigo naturalis is in the form of dry powder or mass prepared from leaf or stem and leaf of Indigofera tinctoria of Acanthaceae and Isatis tinctoria of Polygonaceae. Salty in nature and cold in flavor. Meridian tropism enters liver meridian. The functions are mainly used for clearing heat and cooling blood, clearing liver and purging fire, purging liver fire, stopping fright epilepsy, clearing heat and toxin and removing food retention.
Herba seu radix Cirsii Japonici is the whole herb and root of herba seu radix Cirsii Japonici of Cirsium of Compositae. Sweet in nature, bitter and cool. Meridian tropism enters heart and liver meridians. The functions are mainly to cool blood and stop bleeding, remove stasis, remove blood stasis and eliminate carbuncle and swelling.
The radix et rhizoma Rhei is dry root and rhizome of Rheum palmatum L., Rheum tanguticum Maxim. Ex Balf. or Rheum officinale Baill. of Polygonaceae. Bitter in property and cold in nature. Meridian tropism includes spleen, stomach, large intestine, liver and pericardium. The functions are mainly used for purging heat and relaxing bowels, cooling blood and removing toxin, removing stasis and relaxing channel, removing heat toxin, breaking accumulation and stagnation and removing blood stasis.
The radix Gentianae Marcrophyllae is dried root of radix Gentianae Marcrophyllae of Gentianaceae, radix Gentianae Marcrophyllae, and radix Gentianae Marcrophyllae. Pungent, bitter and mild in nature. Meridian tropism enters stomach, liver and gallbladder meridians. The main functions are moistening but not drying, bitter in flavor can purge, pungent in flavor can disperse, warm in nature can smooth, clear heat and promote diuresis, dispel wind-damp, clear damp-heat and stop arthralgia.
Herba Lobeliae chinensis is root-carrying whole plant of herba Lobeliae chinensis of Campanulaceae. Pungent and mild in nature and flavor. Meridian tropism includes heart, small intestine and lung meridian. The functions are mainly used for inducing diuresis to alleviate edema, clearing away heat and toxic materials, treating jaundice and removing sore toxins.
The radix Ampelopsis refers to dry root tuber of Ampelopsis japonica Makino of Vitaceae. Bitter and pungent in property, slightly cold. Meridian tropism is heart and stomach meridian tropism. The functions are mainly used for clearing away heat and toxic materials, mainly treating carbuncle, swelling, deep-rooted carbuncle and sore, resolving masses and relieving pain.
The radix Angelicae Dahuricae is dry root of Angelica dahurica or Angelica dahurica of Umbelliferae. Pungent and warm in nature and flavor. The meridian tropism is entered in stomach, large intestine and lung meridians. The functions are mainly used for dispelling wind and eliminating dampness, dredging orifices and relieving pain, and reducing swelling and expelling pus.
The Carthami flos is dried flower of Carthamus Tinctorius of Compositae. Pungent and warm in nature and flavor. Meridian tropism enters heart and liver meridians. The functions are mainly used for activating blood and stimulating the menstrual flow, inducing diuresis and reducing edema, and removing blood stasis and relieving pain.
The Saviae Miltiorrhizae radix is dried root and rhizome of Salvia miltiorrhiza Bunge of Labiatae. Bitter in property and slightly cold in nature. Meridian tropism enters heart and liver meridians. The functions are mainly used for promoting blood circulation, dredging channels, removing blood stasis, relieving pain, expelling pus and relieving pain.
The Solanum nigrum L is whole plant of Solanum nigrum L of Solanaceae. Bitter in property and cold in nature. Has little toxicity. Meridian tropism enters stomach and gallbladder meridians. The functions are mainly used for treating furuncle, carbuncle and swelling, activating blood circulation, clearing heat, detoxifying, inducing diuresis and relieving swelling.
The Glycyrrhrizae radix is dried root of Glycyrrhrizae radix of Leguminosae, such as Glycyrrhiza inflata L.or Glycyrrhiza glabra L.. Sweet in nature and taste, neutral in nature. Meridian tropism includes heart, lung, spleen and stomach meridians. The functions are mainly used for clearing away heat and toxic material, relieving spasm and pain and harmonizing the medicines.
The invention relates to an external traditional Chinese medicine composition for treating cholecystitis, which has the central principle of 'Tong, Li'. Aiming at the pathogenesis of cholecystitis, the traditional Chinese medicine composition is used for clearing heat, activating blood, soothing liver, promoting diuresis, benefiting gallbladder and benefiting qi by a method of promoting diuresis. In the formula, the scorpion, the Japanese thistle herb, the rhubarb, the angelica dahurica, the safflower, the salvia miltiorrhiza, the indigo naturalis and the black nightshade have the effects of benefiting qi, promoting qi circulation, dispersing liver qi, activating blood, benefiting gallbladder and relieving pain; the ginger, the costustoot, the corn stigma, the rhubarb, the Chinese lobelia herb and the gentiana macrophylla have the effects of clearing away damp-heat, purging heat and toxin, removing food retention, eliminating jaundice and soothing liver and gallbladder; scorpio, radix aucklandiae, herba seu radix Cirsii Japonici, radix Gentianae Marcrophyllae, radix Ampelopsis, radix Angelicae Dahuricae, Carthami flos, and Saviae Miltiorrhizae radix have effects of resolving hard mass, relieving pain, removing blood stasis and relieving pain; stigma Maydis, indigo naturalis, herba Cisii Eriophoroidei, radix et rhizoma Rhei, radix Gentianae Marcrophyllae, herba Lobeliae chinensis, radix Ampelopsis, radix Angelicae Dahuricae, herba Solani Nigri, and Glycyrrhrizae radix have effects of clearing heat and removing toxic substances, clearing hollow viscera and purging pathogenic fire, nourishing yin and softening liver; the safflower, the salvia miltiorrhiza, the corn stigma, the gentiana macrophylla, the Chinese lobelia, the angelica dahurica, the black nightshade and the liquorice have the effects of activating blood and removing stasis and activating water and dampness; the ginger, the costustoot and the natural indigo have the effects of warming the middle-jiao and strengthening the spleen, and harmonizing the stomach; the liquorice has the functions of harmonizing all the drugs, and the ginger, the costustoot, the safflower and the salvia have the functions of fragrance permeation, dredging blood vessels, smoothing hair orifices, guiding drugs to move forward, promoting the active ingredients of the drugs to permeate and absorb from skin pores, and the like. For example, in Ben Cao Jing Shu, the bitter herbs can purge, pungent herbs can disperse, sweet herbs can relieve, cold herbs can remove heat, so it is mainly indicated for abscess, swelling, ulcer, and pain, in Ben Cao Zheng Yi, the bitter herbs can purge, clear away damp-heat and remove stasis, in Yi Yao Hua, it is good at dredging meridians, and is a blood-qi-activating herb, and can purge and tonify, and there is a wonderful meaning, in Ben Cao Jing, it is indicated for Gentiana macrophylla, bitter herbs can purge, pungent herbs can disperse, and slightly warm can promote diuresis, so it is mainly indicated for cold-heat pathogen, cold-damp arthralgia, pain in limbs, water drainage, and diuresis. It has actions of dispelling wind and removing dampness … …, and also has actions of removing dampness and resolving hard mass, and clearing intestine and stomach, so in Yao Hua Yi (medical science) it is said that mu Xiang can ventilate and combine five zang organs as essential herbs for regulating qi. The medicines are used together, the medicine formula is strict, the effects of all the medicines are selected, and the medicines are compatible, so that the effects of soothing the liver, promoting the function of gallbladder, clearing heat, removing toxicity, promoting diuresis, removing blood stasis and relieving pain are achieved together due to the fact that the medicines are conducted with the advantages of the functions of promoting digestion, eliminating dampness, clearing heat and removing toxicity, and the effects of treating cholecystitis are achieved.
The invention relates to an externally applied traditional Chinese medicine composition for treating cholecystitis, which takes the integral treatment theory of traditional Chinese medicine as guidance, and adopts an externally applied medicine for treating cholecystitis by using a traditional Chinese medicine external treatment method, namely a surgical method, which is the most important external treatment method. Ri \28729ZhouFang said that all the diseases are treated externally, so the doctor has the external treatment method. The internal treatment is conducted by taking the external treatment from the interior, and the internal treatment is conducted without teaching a person to perform special internal treatment, namely the external treatment, the external treatment is conducted, namely the internal treatment, the skin is separated from the skin, the hair is communicated, the viscera are not seen, the effective components of the medicine directly reach the viscera, the effective components of the medicine penetrate through pores, communicate with the viscera, directly reach the disease position, cause the internal regulation of the body, and achieve the purpose of treating the cholecystitis by means of pathogenic factors and pathogenic factors.
The preparation method of the externally-applied traditional Chinese medicine composition for treating cholecystitis provided by the invention comprises the steps of preparing and processing the medicinal materials in the formula, preparing the medicinal materials into paste, subpackaging and sealing.
The application method of the invention is as follows: the right upper abdomen part of the gallbladder region is externally applied for administration.
The invention relates to an external traditional Chinese medicine composition for treating cholecystitis, which is administered by adopting an external treatment method. The external application medicine has the advantages of convenient treatment, small irritation and simple operation. Therefore, the externally applied traditional Chinese medicine composition for treating cholecystitis has certain clinical popularization and application values.
EMBODIMENTS FOR CARRYING OUT THE INVENTION
Example 1:
the invention relates to an external traditional Chinese medicine composition for treating cholecystitis, which is prepared according to the following medicine proportioning relation: 2Kg of scorpion (alive, fresh), 7Kg of ginger (fresh), 20Kg of corn stigma (fresh), 6Kg of costustoot, 1Kg of indigo naturalis, 8Kg of Japanese thistle herb, 7Kg of rhubarb, 6Kg of gentiana macrophylla, 7Kg of Chinese lobelia, 6Kg of Japanese ampelopsis, 6Kg of angelica dahurica, 4Kg of safflower, 6Kg of salvia miltiorrhiza, 10Kg of black nightshade and 6Kg of liquorice.
(1) Cleaning rhizoma Zingiberis recens, squeezing, filtering, and discarding residues to obtain rhizoma Zingiberis recens juice; cleaning the above-mentioned dosages of stigma Maydis (fresh), herba seu radix Cirsii Japonici, radix Gentianae Marcrophyllae, herba Lobeliae chinensis, Carthami flos, herba Solani Nigri and Glycyrrhrizae radix, placing in an extractor, adding appropriate amount of purified water, heating and decocting to extract effective components of the medicine, squeezing the residue, separating the medicinal liquid, discarding the residue, filtering, concentrating the filtrate under reduced pressure, adding the ginger juice, mixing well to obtain a thin paste-like concentrated medicine for use;
(2) taking the above amount of Scorpio (live, fresh), adding 95% ethanol solution for inactivation, taking out, draining, and pulverizing into superfine slurry with ultrasonic pulverizer;
(3) cleaning the above radix aucklandiae, indigo naturalis, radix et rhizoma Rhei, radix Ampelopsis, radix Angelicae Dahuricae and Saviae Miltiorrhizae radix, drying, pulverizing into fine powder, and sieving;
(4) mixing the medicines obtained in the steps (1), (2) and (3), stirring uniformly to obtain brown traditional Chinese medicine ointment, and storing in a sealed and dark place.
Example 2:
the implementation method of this embodiment is different from that of embodiment 1 in that: 1Kg of scorpion (alive, fresh), 6Kg of ginger (fresh), 19Kg of corn silk (fresh), 7Kg of costustoot, 1.5Kg of indigo naturalis, 7Kg of Japanese thistle herb, 8Kg of rhubarb, 7Kg of gentiana macrophylla, 8Kg of Chinese lobelia, 5Kg of Japanese ampelopsis, 5Kg of angelica dahurica, 5Kg of safflower, 5Kg of salvia miltiorrhiza, 9Kg of black nightshade and 7Kg of liquorice.
Example 3:
the invention relates to an external traditional Chinese medicine composition for treating cholecystitis, which is prepared according to the following medicine proportioning relation: 3Kg of scorpion (alive, fresh), 8Kg of ginger (fresh), 22Kg of corn stigma (fresh), 5Kg of costustoot, 0.5Kg of indigo naturalis, 9Kg of Japanese thistle herb, 6Kg of rhubarb, 5Kg of gentiana macrophylla, 6Kg of Chinese lobelia, 7Kg of Japanese ampelopsis, 7Kg of angelica dahurica, 3Kg of safflower, 7Kg of salvia miltiorrhiza, 11Kg of black nightshade and 5Kg of liquorice.
(1) Cleaning rhizoma Zingiberis recens, squeezing, filtering, and discarding residues to obtain rhizoma Zingiberis recens juice; cleaning the above-mentioned dosages of stigma Maydis (fresh), herba seu radix Cirsii Japonici, herba Lobeliae chinensis, herba Solani Nigri, radix Angelicae Dahuricae, radix et rhizoma Rhei, and Saviae Miltiorrhizae radix, placing in an extractor, adding appropriate amount of purified water, heating, decocting to extract effective components of the medicine, squeezing the residue, separating the medicinal liquid, discarding the residue, filtering, concentrating the filtrate under reduced pressure, adding the ginger juice, mixing well to obtain a thin paste-like concentrated medicine for use;
(2) taking the above amount of Scorpio (live, fresh), adding 95% ethanol solution for inactivation, taking out, draining, and pulverizing into superfine slurry with ultrasonic pulverizer;
(3) cleaning the above materials, drying, and pulverizing into fine powder;
(4) mixing the medicines obtained in the steps (1), (2) and (3), stirring uniformly to obtain brown traditional Chinese medicine ointment, and storing in a sealed and dark place.
The clinical treatment effect of the externally applied traditional Chinese medicine composition for treating cholecystitis is illustrated by the clinical examples below.
Clinical examples:
1. diagnostic criteria for cholecystitis
The diagnosis standard of cholecystitis is based on the diagnosis and treatment guidelines for acute biliary tract infection (2011 edition) journal of digestive surgery of china, 2011 and 10, the consensus opinions of chronic cholecystitis and cholecystolithiasis in medicine (2014, shanghai), the journal of digestive surgery of china, 2014 and 12, the consensus opinions of Chinese and western medicine experts for cholecystitis (2017), the journal of digestive surgery of chinese and western medicine, 2017 and 4, and the patients who meet the medical treatment guidelines are diagnosed according to the above standard.
2. Case grouping
Acute cholecystitis: 89 cases of acute cholecystitis meet the indication of medicine conservation treatment, and patients have the symptoms of gallbladder wall thickening, gallbladder enlargement, gall-bladder calculus, hydrops of tissues around the gall-bladder and the like in physical examination of ultrasonography B. The random number table is divided into a treatment group and a control group. 46 patients, 20 men and 26 women in the treatment group, age (39 +/-11, 35-51) y patients, weight (65 +/-18, 55-85) kg patients, course (3 +/-1.8, 1-4) d patients, 11 combined gallstones and 5 mild jaundice patients; the control group comprises 43 cases, 19 cases of men and 24 cases of women, patients with age (40 +/-10, 34-51) y, weight (63 +/-17, 53-86) kg, course (3 +/-1.6, 1-4) d, 9 cases of combined gallstone and 4 cases of mild jaundice.
Chronic cholecystitis: 97 cases of chronic cholecystitis meet the medical treatment indexes, and patients have the symptoms of gallbladder wall thickening, fibrosis, gallstone, gallbladder juice accumulation, gallbladder peripheral tissue hydrops and the like in physical examination of B ultrasonic examination. The random number table is divided into a treatment group and a control group. 49 patients, 18 men and 31 women in the treatment group, the age (40 +/-13, 32-54) y, the weight (64 +/-17, 56-83) kg and the course (35 +/-12.3, 8-70) mo of the patients, and 18 combined gallstones; in 48 control groups, 16 men and 32 women, patients are aged (41 +/-14, 32-53) y, weight (64 +/-21, 51-81) kg, course of disease (34 +/-11.8, 7-70) mo, and 19 gallstones are combined.
3. Observation index
Clinical observation indexes of cholecystitis are formulated according to guiding principles (trial) of clinical research on novel traditional Chinese medicine, Zhengxiao Yu, published by Chinese medicine science and technology, 2002.
B ultrasonic examination, conventional blood leukocyte count (WBC), serum C-reactive protein examination, total bilirubin level examination, etc. are performed, and clinical symptom improvement condition, symptom improvement time and cure time of two groups of cholecystitis patients after treatment are observed.
The symptoms such as nausea and vomiting, tenderness of gallbladder (rebound pain), right epigastric pain and the like were scored according to the symptom absence, mild symptom, moderate symptom and severe symptom, respectively, and the symptom score was 0, 3, 6 and 9.
Adverse drug reactions that may occur were observed and recorded.
Statistical data processing, counting data using x2And (5) checking, namely, t checking the metering data. P < 0.05 is statistically significant.
4. Standard of therapeutic effect
The clinical curative effect standard of cholecystitis is formulated according to guiding principle (trial) of clinical research of new Chinese medicine, Zheng Xiao Yu, published by Chinese medicine science and technology, 2002, Chinese journal of digestion by Chinese and Western medicine, 2017, 4, and the consensus opinion (2017) of Chinese expert for diagnosis and treatment of cholecystitis. Cure rate + significant efficacy + effective rate is the total effective rate.
And (3) curing: the gallbladder imaging examination is basically normal, the calculus disappears or decreases, the routine blood examination, the serum C-reactive protein examination and the total bilirubin examination are normal, and the clinical symptoms and physical signs disappear.
The effect is shown: the gallbladder imaging examination is basically normal, the calculus disappears or decreases, the blood routine examination, the serum C-reactive protein examination and the total bilirubin examination result are improved by more than or equal to 70 percent compared with the examination value before treatment, and the symptom sign score value is reduced by more than or equal to 70 percent.
The method has the following advantages: the gallbladder imaging examination is obviously improved, the calculus disappears or is reduced, the blood routine examination, the serum C-reactive protein examination and the total bilirubin examination result are improved by more than or equal to 40 percent compared with the examination value before treatment, and the symptom sign score value is reduced by more than or equal to 40 percent.
And (4) invalidation: the gallbladder imaging examination is not obviously improved, the blood routine examination, the serum C-reactive protein examination and the total bilirubin examination result are improved by less than 40 percent compared with the examination value before treatment, and the symptom sign score value is reduced by less than 40 percent.
5. Method of treatment
5.1 treatment of acute cholecystitis
Both groups of patients were given basal treatment: bed rest, fasting or liquid diet; atropine is given to patients with pain for spasmolysis and pain relief; examining items such as blood conventional white blood cell count (WBC), serum C-reactive protein and the like, and administering cephalosporin drugs and fluoroquinolone drugs to patients with clinical infection indications for anti-infective treatment. Treatment for 5 days is 1 course.
When the treatment group is used for basic treatment, the externally-applied traditional Chinese medicine composition for treating cholecystitis, which is prepared in the invention in the embodiment 1, is added, bid, 20g each time is uniformly coated and externally applied to the gall bladder area of the upper right abdomen, and the application time is 8h each time after the medicine is wrapped by sterile gauze. Treatment for 5 days is 1 course.
5.2 treatment of chronic cholecystitis
All patients in the two groups of patients were subjected to health education and given a low-fat, low-calorie diet and regular diet. The control group was given anti-inflammatory and cholagogic tablets (Guangdong Rooshan national medicine GmbH, national medicine Standard Z44021422) orally, tid, 6 tablets each time. The external traditional Chinese medicine composition for treating cholecystitis, which is prepared in the embodiment 1 of the invention, is applied to a treatment group, bid is 20g each time, the medicine is uniformly coated and externally applied to the gall bladder area of the right upper abdomen, and the application time is 8h each time after the medicine is wrapped by sterile gauze. The treatment course of 15 days is 1 for both groups.
Results of acute cholecystitis treatment
6.1 percent of cure rate and total effective rate
After one treatment course, the treatment group is cured by 16 cases, the curative effect is 12 cases, the effective effect is 17 cases, the ineffective effect is 1 case, the cure rate is 34.8 percent, and the total effective rate is 97.8 percent; the control group has 9 cases of cure, 11 cases of obvious effect, 18 cases of effect and 5 cases of no effect, the cure rate is 20.9 percent, and the total effective rate is 88.4 percent.
After two treatment courses, the treatment groups are cured by 38 cases, 5 cases with obvious effect and 3 cases with effective effect, the cure rate is 82.6 percent, and the total effective rate is 100.0 percent; the control group is cured for 29 cases, the obvious effect is 6 cases, the effective effect is 5 cases, the ineffective effect is 3 cases, the cure rate is 67.4 percent, and the total effective rate is 93.0 percent. The cure rate and the total effective rate of the two groups are compared, the difference has statistical significance (P is less than 0.05), and the treatment group is superior to the control group.
6.2 comparison of symptom relief time
The average time for the nausea and vomiting symptoms to disappear in the treatment group is 2.41 +/-0.82 d, the average time for the gallbladder region tenderness (rebound pain) symptoms to disappear is 1.89 +/-0.73 d, and the average time for the right upper abdomen pain symptoms to disappear is 1.62 +/-0.79 d; the average time for the disappearance of nausea and vomiting symptoms in the control group was 5.85. + -. 1.93d, the average time for the disappearance of gallbladder tenderness (rebound pain) symptoms was 5.69. + -. 2.14d, and the average time for the disappearance of right epigastric pain symptoms was 5.23. + -. 1.87 d. The average time of disappearance of symptoms such as nausea, emesis, gallbladder tenderness (rebound pain), right epigastric pain, etc. in the two groups is compared, the difference has statistical significance (P is less than 0.05), and the treatment group is superior to the control group.
7 results of treatment of chronic cholecystitis
After one treatment course, the treatment group is cured by 13 cases, 20 cases with obvious effect, 9 cases with effect and 7 cases with no effect, the cure rate is 26.5 percent, and the total effective rate is 85.7 percent; the control group has 1 cure, 9 obvious effects, 24 effective cases and 14 ineffective cases, the cure rate is 2.1 percent, and the total effective rate is 70.8 percent.
After two treatment courses, 31 cases are cured in a treatment group, 10 cases are obviously effective, 4 cases are ineffective, the cure rate is 63.3%, and the total effective rate is 91.8%; the control group has 18 cases of cure, obvious effect of 12 cases, effective 8 cases and ineffective 10 cases, the cure rate is 37.5 percent, and the total effective rate is 79.2 percent. The cure rate and the total effective rate of the two groups are compared, the difference has statistical significance (P is less than 0.05), and the treatment group is superior to the control group.
8 clinical evaluation
In the specific implementation of the clinical embodiment, no adverse drug reaction related to the externally-applied traditional Chinese medicine composition for treating cholecystitis is observed, and the externally-applied traditional Chinese medicine composition is safe to apply.
The practice of the clinical embodiment of the externally-applied traditional Chinese medicine composition for treating cholecystitis proves that the composition has better treatment effect on cholecystitis, is convenient and safe to apply and use, and increases treatment means for the diseases. Therefore, the externally-applied traditional Chinese medicine composition for treating cholecystitis has popularization and use values.
Claims (2)
1. An external traditional Chinese medicine composition for treating cholecystitis is characterized in that the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-3 parts of scorpion (living, fresh), 6-8 parts of ginger (fresh), 18-22 parts of corn stigma (fresh), 5-7 parts of elecampane, 0.5-1.5 parts of indigo naturalis, 7-9 parts of Japanese thistle herb, 6-8 parts of rhubarb, 5-7 parts of gentiana macrophylla, 6-8 parts of Chinese lobelia, 5-7 parts of Japanese ampelopsis, 5-7 parts of angelica dahurica, 3-5 parts of safflower, 5-7 parts of salvia miltiorrhiza, 9-11 parts of black nightshade and 5-7 parts of liquorice.
2. The use of the topical Chinese medicinal composition for treating cholecystitis as claimed in claim 1 in the preparation of a topical pharmaceutical preparation for treating cholecystitis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910981506.8A CN110694038A (en) | 2019-10-12 | 2019-10-12 | External traditional Chinese medicine composition for treating cholecystitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910981506.8A CN110694038A (en) | 2019-10-12 | 2019-10-12 | External traditional Chinese medicine composition for treating cholecystitis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110694038A true CN110694038A (en) | 2020-01-17 |
Family
ID=69199679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910981506.8A Pending CN110694038A (en) | 2019-10-12 | 2019-10-12 | External traditional Chinese medicine composition for treating cholecystitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110694038A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1219422A (en) * | 1998-11-03 | 1999-06-16 | 巫茂成 | Medicine for curing hepatic and gallbladder diseases |
CN102406896A (en) * | 2011-11-28 | 2012-04-11 | 孔繁化 | Pharmaceutical composition for treating chronic cholecystitis |
CN103977366A (en) * | 2014-06-06 | 2014-08-13 | 济南高达信息技术有限公司 | Medicine for treating chronic cholecystitis |
-
2019
- 2019-10-12 CN CN201910981506.8A patent/CN110694038A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1219422A (en) * | 1998-11-03 | 1999-06-16 | 巫茂成 | Medicine for curing hepatic and gallbladder diseases |
CN102406896A (en) * | 2011-11-28 | 2012-04-11 | 孔繁化 | Pharmaceutical composition for treating chronic cholecystitis |
CN103977366A (en) * | 2014-06-06 | 2014-08-13 | 济南高达信息技术有限公司 | Medicine for treating chronic cholecystitis |
Non-Patent Citations (1)
Title |
---|
雷一鸣: "《中华名医顽症秘方大全》", 31 July 1999, 广西科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102973862B (en) | Chinese medicine preparation for treating skin itch | |
CN104758890A (en) | Traditional Chinese medicine composition for treating cough | |
CN104689132A (en) | Traditional Chinese medicine composition for treating psoriasis | |
CN101239162B (en) | Traditional Chinese medicine composition for treating stomach disease | |
CN110694038A (en) | External traditional Chinese medicine composition for treating cholecystitis | |
CN105853866A (en) | Method for preparing Chinese herbal medicine composition for treating bedsore | |
CN104645163A (en) | Traditional Chinese medicine composition for treating psoriasis | |
CN105233252A (en) | Chinese and western medicine compound preparation for treating acute suppurative cholangitis | |
CN111643561A (en) | A Chinese medicinal composition for treating menoxenia, dysmenorrhea, and amenorrhea | |
CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
CN104721631A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
CN111265644A (en) | Bone-activating pain-relieving plaster and preparation method thereof | |
CN116688070B (en) | Chinese medicine composition, Chinese medicine preparation, preparation method and application | |
CN105663850A (en) | Traditional Chinese medicine composition for treating oral ulcer | |
CN102743437B (en) | Traditional Chinese medicine composition having function of clearing vivotoxin and preparing method thereof | |
CN106620140A (en) | Traditional Chinese medicine composition for treating foot rot of buffaloes | |
CN104666824A (en) | Traditional Chinese medicinal composition for treating psoriasis | |
CN105193996A (en) | Traditional Chinese medicine composition for treating decubitus and preparation method of traditional Chinese medicine composition | |
CN105833152A (en) | Traditional Chinese medicine composition for treating endocrine dyscrasia | |
CN105687656A (en) | Pharmaceutical composition for treating myelitis and preparation method thereof | |
CN105395765A (en) | External application traditional Chinese medicine preparation for treating chronic nasosinusitis | |
CN104857383B (en) | A kind of pharmaceutical composition for treating dental caries periapical inflammation and its application | |
CN105079487A (en) | Traditional Chinese medicine composition for treating heat stranguria | |
CN104587397A (en) | Traditional Chinese medicinal composition for treating endocrine dyscrasia | |
CN115364185A (en) | Traditional Chinese medicine tablet for treating gastrectasia by dredging and reducing stomach qi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200117 |